@article{discovery10141835,
           pages = {2574--2575},
            note = {This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.},
          volume = {385},
         journal = {New England Journal of Medicine},
            year = {2021},
           title = {Chlorthalidone in Advanced Chronic Kidney Disease - Have We Missed a Trick?},
       publisher = {MASSACHUSETTS MEDICAL SOC},
           month = {December},
          number = {27},
             url = {https://doi.org/10.1056/NEJMe2118149},
            issn = {1533-4406},
        abstract = {Control of hypertension is central to the management of chronic kidney disease, both to preserve residual kidney function and to reduce the associated high risk of cardiovascular events. International guidelines recently updated by the Kidney Disease: Improving Global Outcomes Organization recommend that patients with chronic kidney disease and hypertension be treated to reduce standardized office systolic blood pressure to less than 120 mm Hg, unless there are obvious reasons not to do so. This ambitious target is difficult to achieve with currently available antihypertensive medications, particularly in patients with more advanced chronic kidney disease (stages 4 and 5)},
          author = {Wheeler, DC}
}